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Abstract
The severe acute respiratory syndrome (SARS) epidemic was characterized by increased pathogenicity in the elderly due to
an early exacerbated innate host response. SARS-CoV is a zoonotic pathogen that entered the human population through
an intermediate host like the palm civet. To prevent future introductions of zoonotic SARS-CoV strains and subsequent
transmission into the human population, heterologous disease models are needed to test the efficacy of vaccines and
therapeutics against both late human and zoonotic isolates. Here we show that both human and zoonotic SARS-CoV strains
can infect cynomolgus macaques and resulted in radiological as well as histopathological changes similar to those seen in
mild human cases. Viral replication was higher in animals infected with a late human phase isolate compared to a zoonotic
isolate. While there were significant differences in the number of host genes differentially regulated during the host
responses between the three SARS-CoV strains, the top pathways and functions were similar and only apparent early during
infection with the majority of genes associated with interferon signaling pathways. This study characterizes critical disease
models in the evaluation and licensure of therapeutic strategies against SARS-CoV for human use.
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Introduction
Severe acute respiratory syndrome coronavirus (SARS-CoV)
emerged in 2002 and 2003, resulting in about 8,000 human
infections with an 11% case fatality rate [1]. SARS-CoV is a
zoonotic pathogen that originated from bats and either entered the
human population directly and/or cycled through palm civets and
raccoon dogs as intermediate hosts [2,3]. Advanced age was
significantly associated with increased SARS-related pathogenicity
and deaths due to rapidly progressive respiratory compromise
(acute respiratory distress syndrome [ARDS]) [1,4].
Based on epidemiological studies the SARS-CoV epidemic was
characterized by different phases: zoonotic, early, middle and late
phases [2]. The zoonotic phase was characterized by strains
isolated from palm civets and raccoon dogs in live animal markets.
The early phase was characterized by several independent human
cases, likely due to zoonotic transmission. The middle phase was
characterized by initial human-to-human transmission, whereas
the late phase was characterized by efficient human-to-human
transmission and extensive global spread to over 30 countries.
The SARS-CoV spike (S) glycoprotein has been identified as the
main mediator of virus entry and host range by binding to its
receptor angiotensin 1-converting enzyme 2 (ACE-2) [5,6]. A high
mutation rate of the S glycoprotein was observed between the
different isolates from both animals and humans and several
amino acid changes have been identified as being critical for the
transition from animal-to-human to human-to-human transmis-
sion [6,7,8].
The S glycoprotein has also been identified as a major target of
protective immunity and as such has been the main focus of
vaccine development [9,10]. While most vaccine candidates have
been developed using nearly identical isolates from the late phase
in the epidemic, it is not clear whether these late phase isolates will
provide robust protection against infection with zoonotic and early
human phase isolates, the most likely source of future outbreaks.
Therefore a heterologous challenge model is needed to test cross-
protection efficacy of vaccine candidates.
Currently, several animal models for SARS-CoV exist, including
mice, hamsters, ferrets and non-human primates [11,12,13,14,
15,16,17]. While these models have been used for pathogenesis
studies as well as vaccine development, the majority of these studies
focused on isolates from the late phase of the outbreak. In fact,
heterologous challenge of mice after vaccination against a late phase
S glycoprotein offered only partial protection [18].
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We previously characterized the in vitro and in vivo virulence of
an isogenic panel of recombinant SARS-CoV isolates bearing the
S glycoprotein from zoonotic, early, middle and late phase isolates
[19]. The late and early human phase viruses replicated to high
titers in human ciliated airway epithelial cultures whereas the
zoonotic isolates did not. Interestingly, the early human (GZ02)
and zoonotic phase (HC/SZ/61/03) isolates were lethal in an
aged mouse model resulting in severe lung infection progressing to
an early organizing phase of ARDS and death [19,20].
In this study we compare the pathogenesis of three recombinant
SARS-CoV isolates bearing the S glycoprotein of zoonotic, early
and late phase isolates in cynomolgus macaques. The Urbani
strain and recombinant Urbani SARS-CoV from our molecular
clone have previously been tested in a non-human primate model
[15] and served as a control in the current study. Clinical,
virological and histological parameters as well as the host
responses were compared to more fully understand the effect of
S glycoprotein variation on virus replication and the host response
to SARS-CoV infection with the ultimate goal of characterizing
heterologous challenge models for SARS-CoV vaccine develop-
ment. Importantly, all viruses replicated to near similar titers and
induced similar pathologic changes of mild disease, demonstrating
the availability of heterologous challenge viruses for future vaccine
studies.
Results
Clinical, laboratory, and radiographical observations
Groups of 9 cynomolgus macaques were challenged via the
intratracheal and intranasal routes with the recombinant Urbani,
GZ02 and HC/SZ/61/03 SARS-CoV strains. No overt clinical
symptoms were seen in any of the infected animals. In addition, no
fever was detected on clinical exam days 1, 2, 4, 7, 10 and 14 post
infection. Minor transient lymphopenia was seen on days 1 and 2
p.i. in all infected animals (data not shown). No significant changes
were observed in blood chemistry.
Respiratory disease development was also analyzed by radio-
graphic imaging (X-ray) with first signs of mild interstitial
pulmonary infiltration and peribronchial markings in the lungs
of some animals infected with Urbani as early as day 1 p.i. (data
not shown). On days 2 and 4 p.i. radiological changes in Urbani
infected animals were very similar to day 1 with an additional
decrease in conspicuity of the caudal vena cava (CVC; Fig. 1).
These changes lasted up to day 11 in at least 1 of the animals.
Radiological changes in HC/SZ/61/03 infected animals were
very similar to Urbani infected animals. Interestingly, one animal
showed a clear progression on day 2 with small ventral-most
consolidation in left middle/caudal lung (right lateral view) and
heavy peribronchial markings (Fig. 1). Notable improvement was
seen by day 4 with mild interstitial infiltrates centrally, and
unsharp CVC margins on both lateral views. Surprisingly,
infection with GZ02 did not result in significant radiological
changes early in infection, although mild increase in interstitial
infiltrates could be observed in 1 animal on day 2 (Fig. 1).
Gross pathological findings during necropsies on days 1, 4 and
14 p.i. included enlarged cervical and bronchial lymph nodes,
splenomegaly and adherence of lung lobes to pleura. No lesions
were noticeable on the lungs of any of these animals.
Virus replication
Virus replication of all three SARS-CoV strains was mainly
restricted to the respiratory tract (trachea, bronchi and lung lobes)
and low levels of replication in spleen, cervical and bronchial
lymph nodes (Fig. 2A and B). Viral replication peaked in the
respiratory tract on day 1 p.i. (Fig. 2A) with a reduction in virus
titers and numbers of virus positive tissues on day 4 p.i. (Fig. 2B),
similar to our findings in mice [19]. No infectious virus could be
isolated on 14 days p.i. in any of the tissues (Data not shown).
Virus titers in Urbani infected animals were generally 1 to 2 logs
higher compared to GZ02 and HC/SZ/61/03 infected animals.
Viral RNA could be detected in the lungs of infected animals up to
14 days p.i. (data not shown). The levels of viral RNA were similar
Figure 1. Radiological changes in SARS-CoV infected cynomolgus macaques. Radiologic progression of respiratory disease in Urbani, GZ02
or HC/SZ/61/03 infected animals during clinical exams at days 0, 2 or 4 post infection. White arrows represent infiltration and consolidation.
doi:10.1371/journal.pone.0018558.g001
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for each SARS-CoV strain at each time point but decreased over
time as observed with the viral titers.
As a measure of virus shedding, nasal, oral and rectal swabs
were assayed for infectious virus. In nasal swabs, virus titers peaked
by day 2 but could be detected up to day 7 and 11 p.i. (Fig. 3A)
Virus titers in oral swabs peaked on day 1 and were on or below
detectable titers by day 4 p.i. (Fig. 3B). Low levels of virus
replication could be observed in rectal swabs but only in a few
animals (Fig. 3C).
Histopathology and Immunohistochemistry
Animals infected with any of the three strains of SARS-CoV
showed mild inflammation within the submucosa, and occasional
extension into the mucosa of the trachea and bronchi at day 1 p.i.
compared to controls (Fig. 4A, C, E, G, I, K, M and Fig. 5A). Mild
perivascular inflammation was observed within the lungs as well as
a multifocal, minimal to mild increase of lymphocytes, macro-
phages and fewer neutrophils and eosinophils within the alveolar
septae and alveoli (Fig. 4E, I and M). Rarely, alveolar fibrin,
edema and minimal hemorrhage were observed. Urbani viral
protein could be detected in tracheal epithelial cells and in alveolar
pneumocytes at day 1 p.i. (Fig. 4D and F). Animals infected with
either the GZ02 or HC/SZ/61/03 strains showed multifocal, mild
to moderate (severity increased compared to Urbani strain lesions),
subacute and eosinophilic pneumonitis, alveolitis, and occasional
bronchitis and bronchiolitis at day 1 p.i. (Fig. 4I and M). In some
animals, perivasculitis with edema was observed along with
occasional alveolar fibrin deposits and type II pneumocyte
hyperplasia. GZ02 viral protein could be detected in tracheal
epithelial cells and in low numbers of macrophages and alveolar
pneumocytes in the lung (Fig. 4H and J). HC/SZ/61/03 viral
protein was not detected in the trachea (Fig. 4L), despite the
presence of infectious virus by titration (Fig. 1A), but could be
detected in alveolar pneumocytes in the lung at day 1 p.i. (Fig. 4N).
By day 4 p.i., a persistence of perivasculitis, peribronchiolitis
and peribronchitis was observed with decreased incidence of
alveolar septal pneumonitis and alveolitis in animals infected with
all 3 SARS-CoV strains and inflammatory cells consisted mostly of
macrophages and lymphocytes with few neutrophils (Fig. 5A, C, E,
G, I, K and M). In animals infected with HC/SZ/61/03,
occasional mild accumulations of fibrin and edema within the
alveoli could be observed (Fig. 5M). No virus positive cells were
observed in the trachea at 4 days p.i. in any of the animals (Fig. 5D,
H and L); however, decreased numbers of alveolar pneumocytes
were still positive for viral protein in the lungs of SARS–CoV
infected animals compared to day 1 (Fig. 5F, J and N).
Host gene expression
We previously showed that the host response was different
between mice infected with the 3 different spike glycoprotein
variants [20]. While clinically no differences were observed
between the 3 viruses used in this study, virus replication was
different (Fig. 2) suggesting that there may be differences in host
responses. When comparing the host gene expression in lung tissue
of the 3 virus infected groups with the host response of control
animals, differentially expressed genes were only observed on day
1 p.i. with the highest number of differentially expressed genes in
Urbani infected animals (Fig. 6A). At 1 day p.i. the majority of
differentially expressed genes associated with GZ02 and HC/SZ/
61/03 infection were common for all three viruses (Fig. 6B).
Whereas the majority of genes associated with Urbani infection
were unique.
In order to better understand the biological functions associated
with the host response to SARS-CoV infection, the functional
annotations were determined for the significant differentially
expressed genes using IPA. Interestingly, although Urbani
infection resulted in a higher number of differentially expressed
genes compared to GZ02 and HC/SZ/61/03 infected animals,
both the top 3 functions and canonical pathways were identical for
all 3 SARS-CoV strains. The top functions included antimicrobial
response, inflammatory response and organismal injury (Fig. 6C),
whereas the top 3 canonical pathways included the interferon
signaling, IRF activation and pattern recognition receptor
pathways (Fig. 6D). Fold changes in genes involved in these
pathways were generally higher in Urbani infected animals
compared to GZ02 and HC/SZ/61/03 infected animals
(Table 1) and included interferon inducible genes like interferon-
induced protein with tetratricopeptide repeats (IFIT) 1 and 3,
myxovirus resistance 1 (MX1) and others, as well as signal
transducers and activators of transcription (STATs) and some of
the highest differentially expressed genes included CXCL10,
CXCL11, ISG15 and MX1.
Cytokine production
In order to confirm mRNA expression kinetics of cytokines at
the translational level, the protein levels of pro and anti-
inflammatory cytokines were determined in the lung homogenates
and plasma of control and SARS-CoV infected animals. While
mRNA expression of IL-1ra, MCP-1 and Mip-1a was increased in
SARS-CoV infected animals, this was not significant and therefore
not included in the analyses described above. However in
agreement with the overall host gene expression kinetics, the
levels of IL-1ra, IL-2, IL12/23 (p40), IL-13, MCP-1 and Mip-1a
in lung tissue were elevated in animals infected with the different
SARS-CoV strains compared to those in control animals on days 1
or 4 p.i. peaking on day 1 p.i. (Fig. 7A) but not on day 14 p.i. (data
not shown). Cytokine levels in blood generally did not correlate
with those found in the lung with the exception of MCP-1 which
peaked on day 1 p.i. (Fig. 7B). No significant differences were
found between the 3 SARS-CoV strains.
Discussion
SARS-CoV is a zoonotic pathogen that can cause severe
respiratory disease in humans [1]. The evolution of the virus
throughout the epidemic was characterized by a high mutation
rate in the S glycoprotein and this adaptation correlated with
increased pathogenicity in humans. We previously showed that
mutations in the S glycoprotein can result in differences in
virulence in an aged mouse model of SARS-CoV infection
[19,20]. These mutations also differentially affected replication in
primary human airway epithelial cultures showing that in contrast
to zoonotic SARS-CoV strains, human strains replicated efficient-
ly in these cultures [19]. In this study we used a panel of these
recombinant SARS-CoV bearing variant S glycoproteins to
develop new models of SARS-CoV infection in non-human
primates that could be used to test vaccine candidates and
therapeutics against heterologous challenge.
Several groups have shown that cynomolgus macaques can be
infected with SARS-CoV, although the clinical presentation is
variable [15,21,22,23]. However, these initial studies did not
control for the age of the animals. Advanced age significantly
increases the severity of SARS-CoV infection and was correlated
with increased morbidity and mortality in humans [1]. In a recent
study, SARS-CoV infection in 10–19 year old cynomolgus
macaques resulted in decreased activity and mildly labored
breathing in some animals [24]. In addition, pulmonary
consolidation was observed as well as diffuse alveolar damage.
Pathogenesis of 3 SARS-CoV Strains
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Figure 2. Virus replication by organ in SARS-CoV infected animals. Virus replication was determined in tissues on day 1 (A) and day 4 (B) by
virus titration. Samples from three animals were assayed and analyzed and the mean titers were calculated as pfu/gr. The error bars represent the
standard error of the mean.
doi:10.1371/journal.pone.0018558.g002
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In this study we infected 8–15 year old cynomolgus macaques with
3 recombinant SARS-CoV bearing S glycoprotein variants
however the increased age did not result in overt clinical symptoms
in our cynomolgus macaque model. In comparison, we previously
infected cynomolgus macaques with the newly emerged H1N1
influenza virus which resulted in increased respiratory rates, nasal
discharge, mild-moderate radiographical changes and gross
pathologic lesions in the lungs [25]. One possible explanation
for the differences observed between the 2 SARS-CoV studies is
the use of different SARS-CoV strains. In the current study we
used the Urbani strain, whereas Smits et al used a different strain of
SARS-CoV (HK-39), isolated from one of the earliest Hong Kong
patients, which contains several mutations throughout the genome
[26]. These observed a.a. changes between the Urbani and HK-39
strain may affect the pathogenesis in the cynomolgus macaque
model. In this study the recombinant SARS-CoV strains bearing
the variant S glycoproteins were all constructed in the Urbani
background. We had previously hypothesized that the 3
recombinant SARS-CoV strains would show differences in
replication in non-human primates due to the fact that both the
Urbani and GZ02 strains replicated efficiently in human airway
epithelium, whereas the zoonotic strains including HC/SZ/61/03
did not [19]. This was in agreement with observations in human
cases of SARS-CoV infection where infection with late phase
SARS-CoV strains resulted in more severe disease and efficient
transmission compared to the mild sporadic cases during the
zoonotic phase of the epidemic [2]. It has been shown that the S
glycoproteins of these strains have adapted to more efficient
binding to its receptor ACE2 [7,8,27]. Indeed the epidemic
Urbani strain replicated to higher titers compared to GZ02 and
HC/SZ/61/03, and shedding of these viruses could be detected
primarily in the nasal and oral swabs as a measure for potential
transmission. However, unlike infection in mice [20], no
differences were found in the cell tropism with all 3 SARS-CoV
strains targeting primarily type II pneumocytes. While no viral
antigen was detected in the trachea of HC/SZ/61/03 infected
animals, the recovery of infectious virus from this tissue suggests
that the absence of antigen is unlikely to be due to a difference in
tropism but rather due to limitations in detection.
In addition, the SARS-CoV S glycoprotein has been implicated
in the downregulation of ACE2 expression [20,28,29]. This
downregulation can cause a deregulation of the renin-angiotensin
system and an exaggeration of acute lung failure [30]. We
hypothesize that the SARS-CoV S glycoproteins from the different
zoonotic and human phases of the epidemic may differentially
down-regulate ACE2, resulting in the observed disconnect
between virus replication and pathogenesis. However unlike in
the mouse model, no differences in ACE2 expression could be
observed by gene expression or immunohistochemistry (data not
shown) in cynomolgus macaques, possibly due to the mild disease
progression observed in the current model. While the S
glycoprotein is a major virulence factor [8,19,27], it cannot be
excluded that the additional mutations in the rest of the genomes
of the GZ02 and HC/SZ/61/03 strains could be necessary for a
more virulent phenotype in the cynomolgus macaque model.
In the current model, no gross pathological lesions were evident
in the lungs of these animals. Interestingly, SARS-CoV infection
did result in radiological changes including pulmonary infiltration
and peribronchial markings early during infection. Although
observed earlier, it is similar to what was seen in mild human cases
[31] as well as in animals infected by the IN route [15]. In
contrast, animals infected by the IN and intrabronchial (IB) route
showed early radiological changes in the lower lung lobes [15].
One explanation for the early detection of radiological changes in
the current model is that animals were infected intratracheally
with a high dose of SARS-CoV. Intratracheal instillation resulted
in the presence of a high virus load in the trachea and bronchi of
the animal, and subsequent peribronchial markings observed early
on during infection. Natural infection in human cases would result
from exposure to a lower virus dose and a less efficient route
[32,33]. In contrast, infection by the intrabronchial route results in
initial virus replication in the interstitium, resulting in radiological
Figure 3. Virus shedding in SARS-CoV infected animals. Virus
replication was determined in nasal (A), oral (B) and rectal (C) swabs of
SARS-CoV infected animals by virus titration. Samples from three
animals were assayed and the mean titers were calculated as pfu/mL.
The error bars represent the standard error of the mean.
doi:10.1371/journal.pone.0018558.g003
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changes in the lower lobes early during infection [15]. The
radiological changes correlated with the observed histopathology
in the lungs. While this model did not exhibit the severe diffuse
alveolar damage (DAD), edema and hyaline membrane formation
associated with severe human cases of SARS-CoV infection [34],
alveolitis with edema, fibrin deposits and type II pneumocyte
hyperplasia was observed in some animals infected with the GZ02
and HC/SZ/61/03 strains but not in Urbani infected animals.
This is in agreement with observations in mice where increased
severity of lung pathology also did not correlate with virus
replication in the lung and the Urbani strain replicated to 1–2 log
higher titers compared to the GZ02 and HC/SZ/61/03 strains.
In human cases, upregulation of IFN pathways plus robust
antiviral IFN-stimulated gene (ISG) expression was observed early
during SARS-CoV infection [35]. In addition, several animal
models have shown that an acute and exacerbated host response
results in acute lung injury [20,24]. In the current study we
observed an early upregulation of genes associated with IFN
signaling and activation of IFN related pathways. This early
upregulation has previously been shown in mouse and non-human
primate models of SARS-CoV infection as well as influenza
infection [20,24,36,37]. In particular, early enhanced expression
of interferon-inducible protein-10 (CXCL-10) and monocyte
chemoattractant protein-1 (MCP-1) have been correlated with
an adverse outcome during SARS-CoV infection in humans
[38,39], which was also highly upregulated in this study.
Unfortunately, due to the animal-to-animal variation, differentially
expressed genes could only be identified on day 1 p.i. Interestingly,
no differences were observed in the pathways involved in all 3
SARS-CoV strains, although the number of genes involved in
these pathways were higher in Urbani infected animals compared
to GZ02 or HC/SZ/61/03 infected animals. In addition, the fold-
changes were also greater following infection with the Urbani
strain compared to GZ02 and HC/SZ/61/03. The higher
upregulation of host genes following Urbani infection correlates
with the observed replication. In agreement with the observed host
gene response, expression of both inflammatory and anti-
inflammatory mediators such as IL-1ra, IL-12, IL-13 and MCP-
1 was upregulated in the lungs of infected animals on day 1 p.i.
Upregulation of these genes was previously observed in serum and
peripheral blood mononuclear cells in human cases of SARS
[40,41,42]. In addition, MCP-1 was also found to be upregulated
in plasma from H1N1 influenza infected macaques [25].
In conclusion, this study demonstrates that cynomolgus
macaques can be infected with zoonotic and early human
epidemic phase SARS-CoV strains, as shown by the presence of
infectious virus in the respiratory tract at days 1 and 4. In addition
we show that infection results in prolonged shedding of the virus in
nasal and oral secretions up to 7 days post challenge as a potential
method of transmission. Finally, infection with the 3 SARS-CoV
strains induces host responses early during infection. These data
show that the new cynomolgus macaque models will be important
in testing the efficacy of vaccine candidates or therapeutics against
Figure 4. Histological changes and virus tropism in the
respiratory tract of SARS-CoV infected animals on day 1.
Controls (A, B), Urbani (C, D, E, F), GZ02 (G, H, I, J) and HC/SZ/61/03 (K, L,
M, N) infected animals were euthanized on day 1 and trachea (A, B, C, D,
G, H, K, L) and lung (E, F, I, J, M, N) sections were stained with H&E (A, C,
E, G, I, K, M) or immunohistochemical (IHC) detection of SARS-CoV
nucleoprotein (B, D, F, H, J, L, N) as described in Materials and Methods.
H&E stained sections of trachea (A, C, G, K) with minimally increased
numbers of lymphocytes, macrophages and neutrophils within the
tracheal submucosa (black arrowhead) and occasional extension of
neutrophils into epithelium (black arrow). IHC stained sections of
trachea reveal occasional positively stained epithelial cells in Urbani (D)
and GZ02 (H) infected animals; no positive IHC staining was detected in
trachea sections from control (B) or HC/SZ/61/03 (L) infected animals;
H&E stained lung sections (E, I, M) with alveolar septal walls expanded
by lymphocytes, macrophages and few neutrophils (open arrow, E, I)
and within alveoli (K); (I, M; open arrowhead= fibrin). IHC staining
revealed occasionally positively stained cells with alveolar pneumocyte
morphology (F, J, N). Original magnification= 4006; panels B, E and J
are increased 133%.
doi:10.1371/journal.pone.0018558.g004
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antigenically distinct SARS-CoV strains [43]. To date, the majority
of vaccine studies have focused on the epidemic Urbani strain which
provide limited protection against heterologous strains, especially in
senescent populations that are more at risk for severe disease [10,18].
The epidemic SARS-CoV strains are extinct; however zoonotic
strains may still emerge from animal reservoirs like bats, palm-civets
and raccoondogs. Therefore a SARS-CoV vaccine should confer
long-term protection against replication and shedding of both the
epidemic strains and any zoonotic strain that may emerge.
Materials and Methods
Viruses and cells
The generation and characterization of each of the recombinant
SARS-CoV bearing variant S glycoproteins (Urbani, GZ02 and
HC/SZ/6103) has been described previously [19]. All viruses
were propagated on Vero E6 cells in Dulbecco’s minimal essential
medium (DMEM; Invitrogen), supplemented with 10% fetal
bovine serum, L-Glutamine, penicillin (10,000 IU/mL) and
streptomycin (10,000 IU/mL) at 37uC in a humidified CO2
incubator. All work was performed in a Class II Biosafety Cabinet
under BSL-3 conditions at RML, DIR, NIH.
Animals and Ethical Statement
Healthy, adult female cynomolgus macaques (Macaca fascicu-
laris) were handled in an ABSL-4 containment laboratory at
RML, DIR, NIH. Research was conducted in compliance with the
Animal Welfare Act and other federal statutes and regulations
relating to animals and experiments involving animals, and
adhered principles stated in the Guide for the Care and Use of
Laboratory Animals, National Research Council, 1996. The
facility where this research was conducted (RML) is fully
accredited by the Association for the Assessment and Accredita-
tion of Laboratory Animal Care International and has an
approved OLAW Assurance #A4149-01. Research was conduct-
ed under a protocol approved by the Institutional Animal Care
and Use Committee (IACUC) at RML. All steps were taken to
ameliorate the welfare and to avoid the suffering of the animals in
accordance with the ‘‘Weatherall report for the use of non-human
primates’’ recommendations. Animals were housed in adjoining
individual primate cages allowing social interactions, under
controlled conditions of humidity, temperature and light (12-hour
light/12-hour dark cycles). Food and water were available ad
libitum. Animals were monitored (pre- and post-infection) and fed
commercial monkey chow, treats and fruit twice daily by trained
personnel. Environmental enrichment consisted of commercial
toys. All procedures were conducted by trained personnel under
the supervision of veterinarians and all invasive clinical procedures
were performed while animals were anesthetized. Early endpoint
criteria, as specified by IACUC approved score parameters, were
used to determine when animals should be humanely euthanized.
Animal procedures
Thirty female Cynomolgus macaques (Macaca fascicularis; ages
8–15) weighing between 2.5 and 4 kg were distributed evenly in
Figure 5. Histological changes and virus tropism in the
respiratory tract of SARS-CoV infected animals on day 4.
Controls (A, B), Urbani (C, D, E, F), GZ02 (G, H, I, J) and HC/SZ/61/03 (K, L,
M, N) infected animals were euthanized on day 4 and trachea (C, D, G,
H, K, L) and lung (A, B, E, F, I, J, M, N) sections were stained with H&E (A,
C, E, G, I, K, M) or immunohistochemical (IHC) detection of SARS-CoV
nucleoprotein (B, D, F, H, J, L, N) as described in Materials and Methods.
H&E stained sections of trachea (C, G, K) with lymphocytes,
macrophages, eosinophils and neutrophils within submucosa (black
arrowhead) and intraepithelial neutrophils (black arrow). IHC stained
sections of trachea (D, H, L) with no positive staining of tracheal
epithelium. H&E stained sections of lung (A, E, I, M) with alveolar and
perivascular aggregates of macrophages and lymphocytes (E, I, M) and
same cells expanding alveolar septae (I, open arrow). (M, asterisk =
blood vessel; open arrowhead= fibrin). IHC stained sections of lung (F, J,
N) with occasional positively stained pneumocytes (black arrow).
Original magnification= 4006; panels C, G and K are increased 133%.
doi:10.1371/journal.pone.0018558.g005
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regards to age and weight over four groups (9 animals per virus
group and 3 animals in a control group). Animals were infected
with either Urbani, GZ02 or HC/SZ/61/03 under anesthesia
through a combination of intratracheal (4 ml) and intranasal
(0.5 ml per nostril) installation with a suspension containing 26106
plaque forming units (pfu) per ml DMEM (total infectious
dose = 16107 pfu) of each of the 3 different SARS-CoV strains.
Three animals were mock infected with virus culture medium only
(DMEM+10% FCS+p/s). Animals were anesthetized for chal-
lenge, clinical examination, temperature, respiration rate, chest
radiographs, blood draw and swabs of nasal, oral and rectal
mucosa on days 0, 1, 2, 4, 7, 11 and 14 p.i. Three animals from
Figure 6. Host gene expression on day 1 after SARS-CoV infection. (A) The number of differentially expressed genes are the result of a
comparison of gene expression in the lungs of SARS-CoV infected cynomolgus macaques versus gene expression in the lungs of mock-infected
animals, and genes were included if they met the criteria of an absolute change of $2-fold (P#0.05. (B) The Venn diagram shows the overlap of
unique and common genes with $2-fold (P#0.01) between Urbani, GZ02 and HC/SZ/61/03. Functional annotations (C) and canonical pathways (D)
were determined in order to better understand the biological functions associated with SARS-CoV infection in cynomolgus macaques.
doi:10.1371/journal.pone.0018558.g006
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each infected group and 1 control animal were euthanized and
necropsied on days 1, 4 and 14 p.i. with collection of clinical
specimens from oral and nasal mucosa, trachea, left and right
bronchi, left and right lung (upper, middle and lower lobes),
spleen, liver, kidney, heart, cervical and bronchial lymph nodes.
Chest radiographs
A mobile digital radiography unit with a flat panel digital
detector (Sound Technologies tru/Dr) and a portable x-ray
generator (Poskom model PXP-HF) was used to acquire chest
radiographs. The system operates on veterinary specific software
system (Vetpacs). Animals were positioned for ventrodorsal
radiography by using a Lexan v-shaped thoracic positioner.
Radiographic views acquired included ventrodorsal, right lateral,
and left lateral thoracic images while under anesthesia. The digital
images were interpreted and assigned a numeric score by a
veterinary radiologist who was blinded to the study design (JM). A
score on a scale of 0–3 based on severity of radiographic changes
were assigned to each set of radiographs (ventrodorsal, right lateral
and left lateral) at each time point. Radiographs were evaluated
and scored using the following criteria: Grade 0, normal
examination; Grade 1, mild interstitial pulmonary infiltrates;
Grade 2, moderate interstitial infiltrates, this may include partial
cardiac border effacement and small areas of pulmonary
consolidation (alveolar patterns and air bronchograms); and
Grade 3, pulmonary consolidation as the primary lung pathology,
seen as a progression from Grade 2 lung pathology.
Hematology and blood biochemistry
Total white blood cell (WBC) count, lymphocyte, platelet,
reticulocyte and red blood cell counts, hemoglobin, hematocrit
values, mean cell volume, mean corpuscular volume and mean
corpuscular hemoglobin concentrations were determined from
EDTA blood with the HemaVet 950FS+ laserbased hematology
analyzer (Drew Scientific). Serum biochemistry was analyzed from
heparin blood using the blood chemistry analyzer, iSTAT1
(Abbott Point of Care). Using the EC8+ Cartridge, urea nitrogen
(BUN), glucose, chloride, sodium, potassium, hematocrit, hemo-
globin, pH, PCO2, TCO2, base excess (BEecf), and anion gap
values were determined; creatinine values were evaluated using the
Crea cartridges.
Cytokine analysis
Concentrations of G-CSF, GM-CSF, IFNc, IL-1b, IL-1ra, IL-2,
IL-4, IL-5, IL-6, IL-8, IL-10, IL-12/23 p40, IL-13, IL-15, IL-17,
MCP-1, MIP-1a, MIP1b, sCD40L, TGFa, TNFa and VEGF in
plasma of animals was determined on days 0, 1, 2, 4, 7, 11 and 14
p.i. and in lung homogenates on days 1, 4 and 14 p.i. using a Non-
Human Primate Cytokine MILLIPLEX map kit (Millipore Corp.)
as described by the manufacturer. Samples were read using a Bio-
Plex 200 system (Bio-Rad).
Virus titrations
Nasal, oral and rectal swabs were collected and stored in 1 ml
DMEM and vortexed for 30 seconds. Tissue samples were
weighed and homogenized in 10 equivalent volumes of DMEM
to generate a 10% solution. The solution was centrifuged at
10,000 rpm under aerosol containment in a table top centrifuge
for 5 min. Supernatants from swabs and tissue homogenates were
serially diluted in DMEM, and 200 ml volumes of each dilution
were placed onto monolayers of Vero-E6 cells in six-well plates.
Following 1 hour of incubation at 37uC, the cells were overlaid
with 0.8% agarose-containing medium. Two days later, the plates
were stained with crystal violet and the plaques were counted.
Titers were calculated as plaque forming unit (pfu) per ml or gr for
swabs and tissues respectively. Titers were graphed using
GraphPad Prism.
Histopathology and immunohistochemistry
All tissues were inactivated and fixed in 10% phosphate-buffered
formalin for at least 7 days prior to being processed by conventional
methods, embedded in paraffin, sectioning at 5 mm thickness and
Table 1. The top differentially upregulated genes belonging to the interferon signaling and immune response pathways.
Fold Change
Gene Symbol RefSeq Transcript ID Urbani GZ02 HC/SZ/61/03
Interferon signalling IFIT1 XM_001086535 18 14 14.6
IFIT3 XM_001086192 24.9 16.6 19.6
IFITM1 XM_001085444 7.8 6.5 6.7
IRF1 XM_001104294 8.8 6.9 -
ISG15 XM_001088541 57.4 51 45.4
MX1 XM_001107646 46 39.4 21.9
OAS1 XM_001110682 23 11.5 14.4
SOCS1 XM_001104595 5.5 - -
STAT1 XR_009921 6.2 6 6.4
STAT2 XM_001115072 8.6 7.1 5.1
TAP1 XM_001115506 3.7 - -
Immune response CCL8 NM_001032851 20.3 8.6 14
CXCL10 NM_001032892 35.6 22.4 14.7
CXCL11 NM_001032950 15.9 25.2 22
IL-1ra XM_001091833 6.9 11 6.7
IL-29 XM_001085768 7.5 2.9 3.5
doi:10.1371/journal.pone.0018558.t001
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hematoxylin and eosin staining. Slides were evaluated by a veterinary
pathologist (D.G.). Tissues for immunohistochemistry were stained
on the Discovery XT automated stainer (Ventana Medical Systems)
using the anti-SARS-nucleoprotein antibody (Imgenex) and the DAB
map detection kit (Ventana Medical Systems). Non-immune rabbit
IgG was used as a negative staining control.
Microarray analysis
Tissue samples were placed in RNAlater (Qiagen) for 11 days at
4uC. RNAlater was removed and samples were homogenized in
1 ml of Trizol for subsequent RNA extraction. Upon thawing,
200 ml chloroform was added, vials were vortexed, and centrifuged
at 16,0006g for 15 min. RNA containing aqueous phase of 350–
550 ml was collected from each sample and passed through
Qiashredder column (Qiagen) at 21,0006 g for 2 minutes to
homogenize any remaining genomic DNA in the aqueous phase.
RNA was purified using RNeasy 96 kit (Qiagen) as described
previously except RNA samples were treated with DNase I during
extraction [44].
An aliquot of sample RNA was used to quantify the three
SARS-CoV strains (Urbani, GZ02, & HC/SZ/61/03). RNA
extracted from a viral stock of the SARS-CoV Urbani strain was
serial diluted and used as standard curve on all three Q-PCR
plates. AgPath-ID One Step PCR kit (Ambion) was utilized with
published SARS-CoV primers and probe [22]. A Q-PCR master
mix was prepared according to manufacturers recommendations
(Ambion). Viral gene expression was expressed as pfu equivalents
per mg total RNA from lung tissues.
Five nanograms of RNA sample from tissue with comparable
viral RNA levels within each group of animals was processed
according to manufacturer’s instructions using WT-OvationTM
Pico system RNA Amplification System (Nugen Inc.). Each sample
was fragmented and labeled according to manufacturer’s instruc-
tions for standard format anti-sense (AT) GeneChip arrays (Nugen
Inc). Samples were hybridized onto Affymetrix GeneChip Rhesus
Macaque Genome Arrays (Affymetrix) according to manufactur-
er’s recommendations. Each chip was scanned using the
Affymetrix 7Gplus GeneChip scanner to create the image files
(dat). GeneChip Operating Software (GCOS v1.4) was then used
to convert the image files to cell intensity data (cel files). The cel
files were input into Partek Genomics Suite software (Partek, inc.
St. Louis, Mo., v6.5 6091110) and quantile normalized to produce
the significant probe set lists at the 0.05 significance level with
multiple test corrections using the false discovery rate method to
determine each probe set p-value. Functional annotations of
significant differentially expressed genes were identified using
Ingenuity Pathway Analysis (IPA; Ingenuity Systems). All micro-
array data is deposited in gene expression omnibus GSE23955
(http://www.ncbi.nlm.nih.gov/geo/) in accordance with proposed
MIAME standards.
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